LTZ Therapeutics said the FDA cleared its IND for LTZ-232, enabling initiation of a Phase 1 study in patients with advanced metastatic colorectal cancer and other solid tumors. The clearance puts the program on track for clinical dosing after regulators accepted the company’s preclinical package and proposed early protocol. LTZ-232 adds to the growing set of oncology INDs entering early testing for heavily pretreated metastatic disease settings. For patients, the immediate effect is access to a clinical investigation pathway; for investors, IND clearance can mark a key de-risking milestone. The Phase 1 enrollment and early safety and tolerability readouts are expected to become the primary drivers for next-step planning, including potential expansion cohorts.